What is Rybelsus used for
All these studies have proven cardiovascular safety for the respective DPP-4 inhibitors
Two vials means two chances for contamination, label error, or sub-spec material
It could potentially reduce the risk of heart disease and stroke, making it an even more compelling option for individuals with obesity and cardiovascular risk factors
this difference may result from a ~5x stronger effect produced by GLP-1 analogs, compared to DPP-4 inhibitors (Charbonnel & Cariou, 2011) No change in weight Contraindications: type I diabetes (these patients lack pancreatic beta cells) diabetic ketoacidosis (it would not be effective for treating this condition) an association between DPP-4 inhibitors and heart failure has been observed for two members of this drug class in patients with type 2 DM and atherosclerosis
This approach may reduce gastrointestinal side effects by up to 70%, improve medication tolerability, and lower monthly costs